Skip to main content
OpenTrials
Completed

NCT Number: NCT02486289

Pilot Proof of Concept Study of NBMI Treatment of Mercury Intoxication

A randomized, placebo controlled, double blind proof of concept study of NBMI in treatment of mercury intoxication.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Hospital Doctor Humberto Molina

Zaruma, Ecuador

About this study

The objectives of this study are to evaluate the efficacy and safety of two doses of NBMI compared to placebo in mercury intoxicated patients.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects, age between 18 and 65 years, inclusive.
  • Urine-Hg ≥ 15 μg/L.
  • Mercury intoxication medical score sum (Doering et al. 2014) ≥ 5 or medical score sum ≥ 3 in combination with at least two of the following symptoms; social nervousness/withdrawal, irritability, memory loss, metallic taste, mental- and physical fatigue.
  • Has signed informed consent for participation.
  • Willingness and ability to comply with study procedures, visit schedules, and other instructions regarding the study.

Exclusion criteria

  • History of any clinically significant disease or disorder which, in the opinion of the investigator, may either put the subjects at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
  • Known or a medical history of renal disorder, significant renal failure, or high risk of renal failure.
  • Any clinically significant abnormalities in clinical chemistry or haematology results at the time of screening as judged by the investigator.
  • Known or suspected neurodegenerative disorder including but not limited to stroke, polio, Parkinson's and Alzheimer's disease.
  • Known or suspected drug or alcohol abuse.
  • Positive pregnancy test in women.
  • Serious bacterial and chronic viral infection such as human immunodeficiency virus (HIV) or hepatitis virus.
  • History of severe allergy/hypersensitivity or on-going allergy/hypersensitivity, as judged by the investigator or history of hypersensitivity to drugs with a similar chemical structure or class to NBMI.
  • History of allergy/hypersensitivity to bisulphites (e.g. red/white wine).
  • Participation in any other clinical study that included drug treatment within three months of the first administration of investigational product.
  • Use of other therapies for mercury intoxication including metal chelators within three months.
  • Investigator considers subject unlikely to comply with study procedures, restrictions and requirements.

Treatment and study plan

Emeramide

Drug

Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)

Other names: NBMI, Irminix

Placebo

Drug

NBMI Placebo

Primary outcomes

  1. Mercury Intoxication Medical Score Sum

    Time frame: 45 days

    Changes from baseline in mercury intoxication medical score sum compared between treatment arms.

Secondary outcomes

  1. Individual components of Mercury Intoxication Medical Score Sum

    Time frame: 45 days

    Changes from baseline in individual components of the mercury intoxication medical score sum compared between treatment arms.

  2. Fatigue score

    Time frame: 15 days

    Changes from baseline in fatigues score sum compared between treatment arms.

  3. Neuromotoric functions

    Time frame: 45 days

    Changes from baseline in neuromotoric functions objectively assessed and quantified using computerized systems such as CATSYS compared between treatment arms.

  4. Blood mercury levels

    Time frame: 45 days

    Changes from baseline in blood mercury level compared between treatment arms.

  5. Urine mercury levels

    Time frame: 45 days

    Changes from baseline in urine mercury level compared between treatment arms.

  6. NBMI blood levels

    Time frame: 14 days

    NBMI blood levels 0-24 hours after the first and last dose (day 14 dose)

  7. NBMI urine levels

    Time frame: 14 days

    NBMI urine levels 0-24 hours after the first and last dose (day 14 dose)

  8. Adverse events

    Time frame: 45 days

    Adverse event frequency, type and severity compared between treatment arms.

  9. Safety laboratory assessments

    Time frame: 45 days

    Changes from baseline in clinical chemistry and haematology tests compared between treatment arms.

  10. Vital signs

    Time frame: 45 days

    Changes from baseline in vital signs compared between treatment arms.

Sponsors and collaborators

Lead sponsor

EmeraMed

Industry

Collaborators

  • NBMI Science AB

Registry information

Official study title

A Randomized, Placebo-controlled Study to Explore Safety, Dose and Efficacy of NBMI in a Mercury Intoxicated Population

Acronym: NBMI

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jul 1, 2015
Registry last updated
Mar 8, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.